Lilly to invest $1.2 billion+ to boost oral medicine manufacturing capacity in US
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The new plant will manufacture high-quality Type I borosilicate glass tubing
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The new site enables end-to-end production of viral vector gene therapies
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The suite represents a multi-million-dollar investment in equipment upgrades and enhancements to improve the site's capabilities
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Subscribe To Our Newsletter & Stay Updated